Clinical Trials Browser

Thyroid Cancer, Papillary, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms, Glioma, Histiocytosis, Langerhans-Cell, Laryngeal Neoplasms, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Ovarian Neoplasms, Colorectal Neoplasms, Hematologic Neoplasms, Erdheim-Chester Disease, Thyroid Carcinoma, Anaplastic

Clinical Trials

DETERMINE

TROPION

Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer

AKIR001

Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer

DETERMINE

LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer

Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer

NEO-COMBATXL

IMMUNORARE5

Efficacy of Pembrolizumab and Lenvatinib in Patients With Anaplastic Thyroid Cancer

Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer

Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer

CABATEN

Abemaciclib in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer

Inolitazone Dihydrochloride and Paclitaxel in Treating Patients With Advanced Anaplastic Thyroid Cancer

SETHY

Nexavar for Neoadjuvant Treatment of Anaplastic Thyroid Cancer

Study of the Rechallenge Concept in Patients With BRAF-positive Anaplastic Thyroid Cancer After Progression on Anti-BRAF Therapy

ANAPLAST-NEO

A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or Radioidodine Refractory Differentiated Thyroid Cancer

NEO-ATACT

Immunotherapy and Stereotactic Body Radiotherapy (SBRT) for Metastatic Anaplastic Thyroid Cancer

Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer

HOPE

Pembrolizumab, Chemotherapy, and Radiation Therapy With or Without Surgery in Treating Patients With Anaplastic Thyroid Cancer

Ceritinib in Mutation and Oncogene Directed Therapy in Thyroid Cancer

Iodine I 131 in Treating Patients With Thyroid Cancer

Gefitinib in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer That Did Not Respond to Iodine Therapy

TAM-RT

Everolimus in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer

Trial Evaluating Gleevec in Patients With Anaplastic Thyroid Carcinoma

Panthera

Combretastatin A4 Phosphate in Treating Patients With Advanced Anaplastic Thyroid Cancer

Induction Chemotherapy Using Doxorubicin and Cisplatin Followed by Combretastatin A4 Phosphate and Radiation Therapy in Treating Patients With Newly Diagnosed Regionally Advanced Anaplastic Thyroid Cancer

SU5416 and Paclitaxel in Treating Patients With Recurrent, Locally Advanced or Metastatic Cancer of the Head and Neck